FLT3 and acute myeloid leukemia: Midostaurin was the first FDA-approved FLT3 inhibitor, achieving approval in 2017 for the treatment of adult patients with newly diagnosed AML harboring a FLT3 mutation in combination with standard induction chemotherapy [81].